Physician Assistant · New York, NY
NPI
1740610336
Since 2013
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
356 W 18th St
New York, NY, 10011
Phone (212) 271-7200
Groups this clinician bills Medicare through
Medicare paid, 2022
$27K
296 services
Medicare patients, 2022
231
Average age 77
Drug cost, 2024
$2.4M
2,563 prescriptions
Company payments, 2025
$150
From 2 companies
Procedures and visits billed to Original Medicare, 2022
In 2022, the most common Medicare service billed by Ryan K Scanlan was code 99305 (snf e&m), 185 times for 184 patients. In total Ryan K Scanlan billed 296 services in 6 codes, and Medicare paid $27K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99305 SNF E&M | Office | 185 | 184 | $102.71 | $19K |
| 99309 SNF E&M | Office | 87 | 65 | $73.79 | $6,420 |
| 99308 SNF E&M | Office | 15 | 14 | $56.68 | $850 |
Medicare prescription drug claims, 2024
In 2024, the drug Ryan K Scanlan prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 184 prescriptions and refills. In total Ryan K Scanlan wrote 2,563 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 184 | 188 | 34 | $708K |
| Tivicay Dolutegravir Sodium | 112 | 122 | 16 | $282K |
| Rosuvastatin Calcium Generic | 103 | 143 | 27 | $899 |
| Atorvastatin Calcium Generic | 100 | 174 | 28 | $509 |
| Prezcobix Darunavir/Cobicistat | 88 | 88 | Under 11 | $215K |
| Losartan Potassium Generic | 69 | 111 | 16 | $270 |
| Juluca Dolutegravir/Rilpivirine | 69 | 71 | Under 11 | $235K |
| Valacyclovir Valacyclovir Hcl | 56 | 94 | 15 | $1,796 |
| Dovato Dolutegravir Sodium/Lamivudine | 53 | 55 | Under 11 | $166K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 49 | 57 | Under 11 | $193K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 48 | 48 | Under 11 | $1,179 |
| Lisinopril Generic | 45 | 56 | Under 11 | $75.26 |
| Tamsulosin Hcl Generic | 42 | 74 | 14 | $366 |
| Pifeltro Doravirine | 39 | 43 | Under 11 | $73K |
| Emtricitabine-Tenofovir Disop Emtricitabine/Tenofovir (Tdf) | 35 | 57 | Under 11 | $24K |
Brand drugs: - claims; generic drugs: 1,608 claims; opioid claims: 26.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ryan K Scanlan $150 ($150 in general payments such as food, travel and fees) from 2 companies. The largest payer was Gilead Sciences, Inc. with $78.96.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.